Aligos Therapeutics (ALGS) Non-Current Assets (2019 - 2026)

Aligos Therapeutics has reported Non-Current Assets for 8 years, with the latest figure at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 34.23% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $23.7 million (down 28.84% YoY), and the FY2025 full-year result was $5.7 million, down 28.69% from the prior year.
• Non-Current Assets for Q1 2026 stood at $4.9 million, down from $5.7 million in the prior quarter.
• The five-year high for Non-Current Assets was $15.4 million in Q1 2022, with the low at $4.9 million in Q1 2026.
• Historically, Non-Current Assets has averaged $10.0 million across 5 years, with a median of $9.8 million in 2024.
• The largest YoY upside for Non-Current Assets was 4.62% in 2022 against a maximum downside of 57.51% in 2022.
• Aligos Therapeutics' Non-Current Assets stood at $13.1 million in 2022, then fell by 20.57% to $10.4 million in 2023, then retreated by 23.84% to $8.0 million in 2024, then declined by 28.69% to $5.7 million in 2025, then decreased by 13.08% to $4.9 million in 2026.
• The last three Non-Current Assets figures came in at $4.9 million (Q1 2026), $5.7 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.